Codon optimized synthetic plasmids

Details Codon optimized synthetic plasmids Codon optimized synthetic plasmids

2003-07-15

2008-01-08

Sullivan, Daniel M. (Department: 1636)

Chemistry: molecular biology and microbiology

Vector, per se

C536S023500, C536S024100, C514S04400A

Reexamination Certificate

active

07316925

ABSTRACT:
One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.

REFERENCES:
patent: 5061690 (1991-10-01), Kann
patent: 5134120 (1992-07-01), Boyd
patent: 5292721 (1994-03-01), Boyd
patent: 5756264 (1998-05-01), Schwartz et al.
patent: 6114148 (2000-09-01), Seed
patent: 6423693 (2002-07-01), Schwartz et al.
patent: 6551996 (2003-04-01), Schwartz
patent: 6924365 (2005-08-01), Miller et al.
patent: WO 01/06988 (2001-02-01), None
patent: WO 01/66149 (2001-09-01), None
patent: WO 02/061037 (2002-08-01), None
Verma et al. (1997) Nature 389:239-242.
Marshall (1995) Science 269:1050-1055.
Orkin et al. (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy, published online at http://www.nih.gov
ews/panelrep.html.
Eck et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, Chapter 5, McGraw-Hill, NY.
Ross et al. 1996 Human gene Therapy 7:1781-1790.
Rubanyi (2001) Mol. Aspects Med. 22:113-142.
Schwaab et al. (2001) Semin. Thromb. Hemost. 27:417-424.
Rissanen et al. (2001) Eur. J. Clin. Invest. 31:651-666.
MacColl et al. (1999) J. Endocinol. 162:1-9.
Plasmid map for pBS, http://www.stratagene.com/vectors/maps/pdf/pbs.gif.
Ahara, H. and Miyazaki, J. (1998). Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16, 867-870.
Baird, A., Wehrenberg, W. B., and Ling, N. (1986). Relative potencies of human, rat, bovine/caprine, porcine and ovine hypothalamic growth hormone-releasing factors to release growth hormone by the rat anterior pituitary in vitro. Neuroendocrinology 42, 273-276.
Bercu, B. B., Walker, R. F., (1997). Growth Hormone Secretagogues in Children With Altered Growth. Acta Paediatrica 86, 102-106.
Blethen, S. L. (1995). Complications of growth hormone therapy in children. Curr. Opin. Pediatr. 7, 466-471.
Blethen, S. L. and Rundle, A.C. (1996). Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. Horm. Res. 46, 113-116.
Bohlen, P., Esch, F., Brazeau, P., Ling, N., and Guillemin, R. (1983). Isolation and characterization of the porcine hypothalamic growth hormone releasing factor. Biochem. Biophys. Res. Commun. 116, 726-734.
Bohlen, P., Wehrenberg,W. B., Esch, F., Ling, N., Brazeau, P., and Guillemin, R. (1984). Rat hypothalamic growth hormone-releasing factor: isolation, sequence analysis and total synthesis. Biochemical & Biophysical Research Communications 125, 1005-1012.
Brazeau, P., Bohlen, P., Esch, F., Ling, N., Wehrenberg,W. B., and Guillemin, R. (1984). Growth hormone-releasing factor from ovine and caprine hypothalamus: isolation, sequence analysis and total synthesis. Biochemical & Biophysical Research Communications 125, 606-614.
Burgert, T. S., Vuguin, P. M., DiMartino-Nardi, J., Attie, K. M., and Saenger, P. (2002). Assessing insulin resistance: application of a fasting glucose to insulin ratio in growth hormone-treated children. Horm. Res. 57, 37-42.
Carrel, A. L. and Allen, D. B. (2000). Effects of growth hormone on body composition and bone metabolism. Endocrine. 12, 163-172.
Corpas, E., Harman, S. M., and Blackman, M. R. (1993a). Human growth hormone and human aging. [Review]. Endocrine Reviews 14, 20-39.
Corpas, E., Harman, S. M., Pineyro, M. A., Roberson, R., and Blackman, M. R. (1993b). Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism 76, 134-138.
Cuttler, L. (1996). The regulation of growth hormone secretion. Endocrinol. Metab Clin. North Am. 25, 541-571.
Danko, I. and Wolff, J. A. (1994). Direct gene transfer into muscle. [Review]. Vaccine 12, 1499-1502.
Darquet, A. M., Cameron, B., Wils, P., Scherman, D., and Crouzet, J. (1997). A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 4, 1341-1349.
Darquet, A. M., Rangara, R., Kreiss, P., Schwartz, B., Naimi, S., Delaere, P., Crouzet, J., and Scherman, D. (1999). Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther. 6, 209-218.
Draghia-Akli, R., Fiorotto, M. L., Hill, L. A., Malone, P. B., Deaver, D. R., and Schwartz, R. J. (1999). Myogenic expression of an injectable protease-resistance growth hormone-releasing hormone augments long-term growth in pigs. Nat. Biotechnol. 17, 1179-1183.
Draghia-Akli, R., Li, X. G., Schwartz, R. J. (1997). Enhanced Growth By Ectopic Expression Of Growth Hormone Releasing Hormone Using An Injectable Myogenic Vector. nature biotechnology 15, 1285-1289.
Draghia-Akli, R., Malone, P. B., Hill, L. A., Ellis, K. M., Schwartz, R. J., and Nordstrom, J. L. (2002). Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. FASEB J. 16, 426-428.
Duck, S. C., et al., (1992). Subcutaneous growth hormone-releasing hormone therapy in growth hormone-deficient children: first year of therapy. Journal of Clinical Endocrinology & Metabolism 75, 1115-1120.
Esch, F., Bohlen, P., Ling, N., Brazeau, P., and Guillemin, R. (1983). Isolation and characterization of the bovine hypothalamic growth hormone releasing factor. Biochemical & Biophysical Research Communications 117, 772-779.
Evans, W. S., Vance, M. L. et al., (1985). Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men. Journal of Clinical Endocrinology & Metabolism 61, 846-850.
Faglia, G., Arosio, M., and Bazzoni, N. (1992). Ectopic acromegaly. [Review]. Endocrinology & Metabolism Clinics of North America 21, 575-595.
Frohman, L. A., Downs, T. R., and Chomczynski, P. (1992). Regulation of growth hormone secretion. [Review]. Frontiers in Neuroendocrinology 13, 344-405.
Frohman, L. A., Downs, T. R., Heimer, E. P., and Felix, A. M. (1989a). Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J. Clin. Invest. 83, 1533-1540.
Frohman, L. A., Downs, T. R., Williams, T. C., Heimer,E.P., Pan,Y.C., and Felix,A.M. (1986). Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J. Clin. Invest. 78, 906-913.
Geffner, M. (1997). Effects of growth hormone and insulin-like growth factor I. Acta Paediatr. Suppl 423, 76-79.
Hart, D. W., Herndon, D. N., Klein, G., Lee, S. B., Celis, M., Mohan, S., Chinkes, D. L., and Wolf, S. E. (2001). Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy. Ann. Surg. 233, 827-834.
Kotzmann, H., Yilmaz, N., Lercher, P., Riedl, M., Schmidt, A., Schuster, E., Kreuzer, S., Geyer, G., Frisch, H., Hori,W. H., Mayer, G., and Luger, A. (2001). Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney Int. 60, 1578-1585.
Lal, S. O., Wolf, S. E., and Herndon, D. N. (2000). Growth hormone, burns and tissue healing. Growth Horm. IGF. Res. 10 Suppl B:S39-43., S39-43.
LeRoith, D., Yanowski, J., Kaldji

Affiliated with

Also associated with

Rating

Codon optimized synthetic plasmids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Codon optimized synthetic plasmids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Codon optimized synthetic plasmids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3963664